21m
iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”
Bio (NASDAQ:IBIO) is seeking to narrow what it views as a growing “trust gap” between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market, ...
In Boston, where anything short of a championship is a failure, the future of sports prediction isn’t coming from instinct — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results